Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy

Journal of the American Academy of Dermatology

Volumn 50, Issue 5, 2004, Pages 792-796

  Powell, Ann Marie ^a,b   Russell Jones, Robin ^a,b  

^a St Thomas' Hospital ^*

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; AGED; AMELANOTIC LENTIGO MALIGNA; ARTICLE; CANCER LOCALIZATION; CANCER SIZE; CASE REPORT; ERYTHEMA; FEMALE; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MALIGNANT LENTIGO; MELANOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 2342467450     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.11.057     Document Type: Article

References (45)

1. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000;143:843-5.
2. Adler MJ, White CR Jr. Amelanotic malignant melanoma. Semin Cutan Med Surg 1997;16:122-30.
3. Clark WH, From L, Bemadino EA, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-26.
4. Ariel IM. Malignant melanoma of the upper extremities. J Surg Oncol 1981;16:125-43.
5. Giuliano AE, Cochran AJ, Morton DL. Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol 1982;9:442-7.
6. Rahbad H, Nabai H, Mehregan AH, Mehregan DA, Mehregan DR, Lipinski J. Amelanotic lentigo maligna melanoma: a diagnostic conundrum: presentation of four cases. Cancer 1996;77:2052-7.
7. Kelly RI, Cook MG, Mortimer PS. Aggressive amelanotic lentfgo maligna. Br J Dermatol 1994;131:562-5.
8. Allan SJR, Dicker AJ, Tidman MJ, Mclaren KM, Hunter JAA. Amelanotic lentigo maligna and amelanotic lentigo maligna melanoma: a report of three cases mimicking intraepidermal squamous carcinoma. J Europ Acad Dermatol Venereol 1998;11:78-81.
9. Rocamora V, Puig L, Romani J, de Moragas JM. Amelanotic lentigo maligna melanoma: report of a case and review of the literature. Cutis 1999;64:53-6.
10. McKenna DB, Cooper EJ, Kavanagh GM, Davie KM, McLaren KM, Tidman MJ. Amelanotic malignant melanoma following cryosurgery for aytpical lentigo maligna. Clin Exp Dermatol 2000;25:600-4.
11. Su WPD, Bradley RR. Amelanotic lentigo maligna. Arch Dermatol 1980;116:82-3.
12. Kiene P, Chrisophers E. From melanotic to amelanotic lentigo maligna: an aggressive variant presenting as an inflammatory lesion. Int J Dermatol 1997;36:123-5.
13. Wayte DM, Helwig EB. Melanotic freckle of Hutchinson. Cancer 1968;21:893-901.
14. Clark WH, Mihm MC. Lentigo maligna and lentigo maligna melanoma. Am J Pathol 1969;55:39-67.
15. Gaspar ZS, Dawber RPR. Treatment of lentigo maligna. Austral J Dermatol 1997;38:1-8.
16. Becker FF. Lentigo maligna and lentigo maligna melanoma recognition and treatment. Arch Otolaryngol 1978;104:352-6.
17. Breuninger H, Schlagenhauff B, Stroebel W, Schaumburg-Lever G, Rassner G. Patterns of local horizontal spread of melanomas: consequences for surgery and histopathologic investigation. Am J Surg Pathol 1999;23:1493-8.
18. Dhawan SS, Wolf DJ, Rabinovitz HS, Poulos E. Lentigo maligna: the use of rush permanent sections in therapy. Arch Dermatol 1990;126:928-30.
19. Mohs FE. Microscopically controlled surgery for periorbital melanoma: fixed-tissue and fresh-tissue techniques. J Dermatol Surg Oncol 1985;11:284-91.
20. Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J Am Acad Dermatol 2002;47:743-8.
21. Roberts DLL, Anstey AV, Barlow RJ, Cox NH, Newton-Bishop JA, Corries PG, et al. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:7-17.
22. Miescher G. Die Behandlung der Malignen Melanome der Haut mit Einschluss der Melanotische Präcancerose. Strahlentherapie 1960;46:25-35.
23. Schmid-Wendtner MH, Brunner B, Konz B, Kaudewitz P, Wendtener CM, Peter RU et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477-82.
24. Arma-Szlachcic M, Ott F, Storck H. Zur Strahlentherapie der Melanotischen Precancerosen. Hautzartzt 1970;21:505-8.
25. Kopf AW, Bart RS, Gladstein AH. Treatment of melanotic freckle with X-rays. Arch Dermatol 1976;112:801-7.
26. Orten SS, Waner M, Dinehart SM, Bardales RH, Flock ST. Q-switched neodymium: yttrium-aluminium-garnet laser treatment of lentigo maligna. Otolaryngol Head Neck Surg 1999;120:296-302.
27. Arndt KA. Argon laser treatment of lentigo maligna. J Am Acad Dermatol 1984;10:953-7.
28. Kopera D. Treatment of lentigo maligna with carbon dioxide laser. Arch Dermatol 1995;131:735-6.
29. Ormond P, Blasdale C, Leonard N, Lawrence CM. Treatment of lentigo maligna with imiquimod. Br J Dermatol 2002;147:57.
30. Chapman MS, Spencer KD, Brennick JB. Histological resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003;139:943.
31. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003;139:944.
32. Steinmann A, Funk JO, Schuler G, von den Driesch P. Topical imiquimod treatment of cutaneous melanoma metastasis. J Am Acad Dermatol 2000;43:555-6.
33. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig.E, Kerl H. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003;139:273-6.
34. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21:1-14.
35. Sauder DN. Immunomodulatory and pharmacological properties of imiquimod. J Am Acad Dermatol 2000;43:6-11.
36. Bridgewater JA, Gore MA. Biological response modifiers in melanoma. Br Med Bull 1995;51:656-77.
37. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumour infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
38. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 1991;97:197-202.
39. Marchand M, Weynants P, Rankin E, Arieti F, Belli F, Parmiani G, et al. Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995;63:883-5.
40. Pfeffer LM, Dinarello CA, Herberman RB, Williams BRG, Borden EC, Bordens R, et al. Biological properties of recombinant alpha-interferons. Cancer Res 1998;58:2489-99.
41. Hofbauer GFL, Geertsen R, Laine E, Burg G, Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res 2001;11:213-8.
42. Palmer KJ, Harries M, Gore ME, Collins MKL. Interferon-alpha (IFN-α) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol 2000;119:412-8.
43. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/ QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
44. von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alfa therapy in advances malignant melanoma. Cancer 1988;66:1071-4.
45. Cornejo P, Vanaclocha F, Polimon I, Del Rio R. Intralesional treatment of lentigo maligna. Arch Dermatol 2000;136:428-30.